Intersect ENT (XENT) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intersect ENT (XENT) PT Raised to $22 at Northland Capital Markets; Medicare Cuts Not Hurting
May 3, 2017 12:25 PM EDTNorthland Capital Markets raised its price target on Intersect ENT (NASDAQ: XENT) to $22.00 (from $17.00) while maintaining a Outperform rating. The firm also raised FY18 numbers.
Analyst Suraj Kalia notes strong growth persists despite Medicare fears. Kalia said commentary indicated relatively muted effect on... More
